BiotechTV - News
BiotechTV
This is the primary news channel of BiotechTV where you will find on the ground reporting by our journalists from biotech hubs throughout the world.
Episodes
Mentioned books
Mar 13, 2025 • 7min
Tour of Scotland: Mark Cook, Co-Chair of Life Sciences Scotland describes the importance of life sciences to the area and what the government and industry are doing to support it
He describes the assets that Scotland has to offer the industry such as excellent universities that derive innovation and a diverse population that makes it a great region for clinical trials.
Mar 13, 2025 • 7min
Tour of Scotland: Glasgow based Mironid is developing a small molecule to directly target aberrantly high cAMP that causes Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Co-Founder & CEO Neil Wilkie walks us through the biology of ADPKD and explains how Mironid is trying to uniquely directly target it. Plus, the growth of the company, investor support, and being based in Glasgow.
Mar 13, 2025 • 9min
Tour of Scotland: Vicki Hazley, Associate Director of The Scottish National Investment Bank, discusses how The Bank invests in life sciences
She describes The Bank's goal of supporting life sciences in Scotland and making a societal impact, how it aims to co-invest with likeminded investors. Plus, examples of investments such as Elasmogen and PneumoWave.
Mar 12, 2025 • 18min
Professor Pieter Cullis and Jay Kulkarni, co-founders of NanoVation Therapeutics, discusses the next generation of lipid nanoparticle delivery
Professor Cullis, one of the original pioneers of LNPs and co-founder of 11 biotechnology companies, describes the challenge of successfully using lipid nanoparticles to deliver payloads to places outside of the liver. Jay Kulkarni, a former postdoc of his who is co-founder and CSO of the company, describes the 'one-stop-shop' capabilities of NanoVation, which has already led to a partnership with Novo Nordisk and others.
Mar 12, 2025 • 11min
Tour of Scotland: Edinburgh based Trogenix is developing an AAV based gene therapy platform for cancer that is designed to deliver combination immune payloads to the tumor
CEO Ken Macnamara describes the science behind this idea and discusses recently presented preclinical data. He highlights the lead program for glioblastoma and plans for the future, and also explains how he believes a patient sample biobank Trogenix has built is key to the company's success in research.
Mar 12, 2025 • 9min
Tour of Scotland: A leading investor who is focused on life sciences in Scotland shares his thoughts on the innovation happening in the area
Andrew McNeill, Managing Partner of St. Andrews based Eos Advisory, introduces us to the firm and some portfolio companies including Dxcover and Laverock Therapeutics.
Mar 12, 2025 • 17min
Acuitas Therapeutics is a pioneer in developing lipid nanoparticals, and already has seen two approved products: ONPATTRO and the Pfizer/BioNTech mRNA vaccine
Co-Founder & CEO Thomas Madden describes the science and history behind LNPs, and discusses what is currently in development, including trying to use them to deliver therapies outside of the liver.
Mar 12, 2025 • 10min
Tour of Scotland: Edinburgh based Cumulus Oncology has built a hub and spoke model of creating multiple spin-out companies - it already has three disclosed assets
Founder & CEO Clare Wareing describes the company's design, with an eye towards being capital efficient and investing over and again for the long-term. She describes the lead investments: a PARG inhibitor, GPR68 small molecules, and a GTPase inhibitor.
Mar 12, 2025 • 8min
Tour of Scotland: Outrun Therapeutics is aiming to create a new category of therapeutics by stabilizing proteins via drugging E3 ligases
CEO Carolyn Porter describes the beginning of the company, which spun out of University of Dundee's MRC Protein Phosphorylation and Ubiquitylation Unit (PPU). The first goal is to go after hard to treat solid tumors.
Mar 11, 2025 • 9min
Tour of Scotland: Tay Therapeutics is a product of University of Dundee's Drug Discovery Unit, and is working on small molecules - including a topical pan-BET that is in phase 2
Founder and CEO Andrew Woodland describes how they made the decision to focus on inflammation for the pan-BET, which is partnered with VYNE Therapeutics. VYNE has also completed a phase 1a with Tay's oral selective BET inhibitor. Plus, how Tay is also working on a small molecule gene therapy program.
